Ticker > Company >

Jenburkt Pharma share price

Jenburkt Pharmaceuticals Ltd.

BSE: 524731 SECTOR: Pharmaceuticals & Drugs  17.73 K   56   3

1067.00
+62.50 (6.22%)
BSE: Today, 02:33 PM

Price Summary

Today's High

₹ 1130

Today's Low

₹ 1020

52 Week High

₹ 1410

52 Week Low

₹ 920.2

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

470.9 Cr.

Enterprise Value

448.23 Cr.

No. of Shares

0.44 Cr.

P/E

14.52

P/B

2.62

Face Value

₹ 10

Div. Yield

1.79 %

Book Value (TTM)

₹  406.88

CASH

24.65 Cr.

DEBT

1.98 Cr.

Promoter Holding

46.66 %

EPS (TTM)

₹  73.5

Sales Growth

6.85%

ROE

20.25 %

ROCE

27.85%

Profit Growth

23.42 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Jenburkt Pharmaceuticals Ltd.

Zydol suspension Triben Zenglobin Zix Powergesic Nervijen Allerzine Glucotrol Pantazole La-Viril

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.85%
3 Year6.96%
5 Year4.99%

Profit Growth

1 Year23.42%
3 Year12.87%
5 Year16.61%

ROE%

1 Year20.25%
3 Year20.07%
5 Year19.87%

ROCE %

1 Year27.85%
3 Year26.98%
5 Year26.33%

Debt/Equity

0.0115

Price to Cash Flow

16.87

Interest Cover Ratio

98.0247

CFO/PAT (5 Yr. Avg.)

0.673624577481895

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 46.66 0.00
Jun 2025 46.67 0.00
Mar 2025 46.68 0.00
Dec 2024 46.69 0.00
Sep 2024 46.71 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 20.0685% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.9768666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 98.0247.
  • The Company has been maintaining an effective average operating margins of 22.4604236141075% in the last 5 years.
  • Company’s PEG ratio is 0.619892380334425.
  • The company has an efficient Cash Conversion Cycle of -32.0172 days.
  • Company has a healthy liquidity position with current ratio of 3.0039.

 Limitations

  • The company has shown a poor revenue growth of 6.95533332567655% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 32.54 41.22 36.89 41.05 35.53
Total Expenditure 23.25 29.79 28.07 30.19 26.57
Operating Profit 9.29 11.43 8.82 10.86 8.96
Other Income 1.41 1.85 1.58 1.88 2.06
Interest 0.12 0.12 0.11 0.11 0.11
Depreciation 0.52 0.64 0.78 0.79 0.72
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.06 12.52 9.51 11.84 10.18
Tax 2.65 2.92 3.01 3.3 2.39
Profit After Tax 7.42 9.6 6.51 8.54 7.79
Adjusted EPS (Rs) 16.8 21.76 14.75 19.34 17.66

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 109.29 123.98 136.75 141.97 151.69
Total Expenditure 89.45 96.73 106.38 108.85 111.3
Operating Profit 19.84 27.26 30.37 33.12 40.39
Other Income 4.31 4.95 5.12 4.67 6.72
Interest 0.47 0.43 0.37 0.27 0.45
Depreciation 2.04 1.9 2.26 2.34 2.73
Exceptional Items 0 0 0 0 0
Profit Before Tax 21.64 29.87 32.86 35.18 43.93
Tax 5.14 7.57 8.26 9.2 11.87
Net Profit 16.5 22.3 24.61 25.98 32.06
Adjusted EPS (Rs.) 35.96 48.58 55.76 58.86 72.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 4.59 4.59 4.41 4.41 4.41
Total Reserves 93.88 112.79 117.98 140.53 167.36
Borrowings 0 0 0 0 0
Other N/C liabilities 3.99 3.92 3.24 2.98 4.12
Current liabilities 17.99 21.28 15.76 16.38 18.82
Total Liabilities 120.45 142.58 141.39 164.3 194.72
Assets
Net Block 10.55 11.4 10.45 10.36 14.66
Capital WIP 0.38 0.21 0.96 1.24 40.28
Intangible WIP 0 0 0 0 0
Investments 6.5 7.96 11.18 16.79 20.56
Loans & Advances 0.32 11.49 11.55 25.36 2.08
Other N/C Assets 22.71 35.61 26.16 0.82 60.61
Current Assets 79.99 75.9 81.09 109.73 56.53
Total Assets 120.45 142.58 141.39 164.3 194.72
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 21.64 29.87 32.86 35.09 43.93
Adjustment -1.6 -2.25 -1.54 -0.49 -3.09
Changes in Assets & Liabilities 5.25 -10.79 -6.05 -18.22 0.49
Tax Paid -5.84 -7.56 -8.22 -8.26 -13.43
Operating Cash Flow 19.45 9.27 17.05 8.12 27.91
Investing Cash Flow -18.78 -1.2 2.62 -0.58 -17.04
Financing Cash Flow -0.71 -5.53 -21.04 -7.08 -7.62
Net Cash Flow -0.04 2.54 -1.37 0.47 3.24

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 46.71 46.69 46.68 46.67 46.66
asha mahesh bhuta - - - 0.85 0.85
ashish uttam bhuta 5.92 5.92 5.92 18.07 18.07
bhavika ashish bhuta 1.17 1.17 1.17 1.17 1.17
bhuta holdings private li... 13.96 13.96 13.96 13.96 13.96
jagruti ketan bhuta 0.63 0.61 0.60 0.59 0.58
kalindi hemendra bhuta 9.06 9.06 9.06 9.06 9.06
kunti ketan gala 1.16 1.16 1.16 1.16 1.16
mahesh harshad bhuta 1.54 1.54 1.54 0.69 0.69
riddhi haresh shroff 0.73 0.73 0.73 0.73 0.73
shivani haresh shroff 0.39 0.39 0.39 0.39 0.39
late. jayshree uttam bhut... - - 12.16 - -
jayshree uttam bhuta 12.16 12.16 - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 53.29 53.31 53.32 53.33 53.34
bharath c jain 1.02 1.02 1.02 1.02 1.02
investor education and pr... - - - - 2.26
kaushik daga 1.02 1.02 1.02 1.02 1.02
nirmala vinodkumar daga 3.30 3.30 3.30 3.30 3.30
parshva kumar daga 1.05 1.05 1.05 1.05 1.05
rajiv garg 1.18 1.08 1.07 1.07 1.07
ranjeet singh sibia 1.49 1.49 1.49 1.49 1.49
sushila paraskumar daga 1.05 1.05 1.05 1.05 1.05
varun daga 1.03 1.03 1.03 1.03 1.03
investor education and pr... 2.06 - 2.13 2.26 -
optirational ventures llp... - 1.15 1.19 1.19 -
investor education and pr... - 2.13 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Jenburkt Pharma - Quaterly Results 12 Aug, 5:38 PM Jenburkt Pharma - Quaterly Results 12 Aug, 5:38 PM Jenburkt Pharma - Quaterly Results 12 Aug, 5:38 PM Jenburkt Pharmaceuticals informs about newspaper publication 23 Jun, 12:51 PM Jenburkt Pharma - Quaterly Results 20 May, 6:50 PM Jenburkt Pharma - Quaterly Results 20 May, 6:50 PM Jenburkt Pharmaceuticals informs about closure of trading window 24 Mar, 4:11 PM Jenburkt Pharmaceuticals informs about newspaper publication 29 Jan, 5:19 PM Jenburkt Pharma - Quaterly Results 28 Jan, 6:45 PM Jenburkt Pharma - Quaterly Results 28 Jan, 6:45 PM Jenburkt Pharma - Quaterly Results 28 Jan, 6:45 PM Jenburkt Pharmaceuticals informs about newspaper advertisement 21 Jan, 4:44 PM Jenburkt Pharmaceuticals informs about newspapers clippings 6 Nov, 5:25 PM Jenburkt Pharma - Quaterly Results 5 Nov, 4:37 PM Jenburkt Pharma - Quaterly Results 5 Nov, 4:37 PM Jenburkt Pharma - Quaterly Results 5 Nov, 4:37 PM Jenburkt Pharmaceuticals informs about board meeting 28 Oct, 2:26 PM Jenburkt Pharmaceuticals informs about loss of share certificate 30 Jul, 12:49 PM Jenburkt Pharmaceuticals informs about newspaper clippings 27 Jul, 2:57 PM Jenburkt Pharma - Quaterly Results 26 Jul, 3:05 PM Jenburkt Pharma - Quaterly Results 26 Jul, 3:05 PM Jenburkt Pharma - Quaterly Results 26 Jul, 3:05 PM Jenburkt Pharma - Quaterly Results 28 May, 5:57 PM Jenburkt Pharmaceuticals informs about issuance of letter of confirmation 2 Mar, 2:34 PM Jenburkt Pharma - Quaterly Results 6 Feb, 4:29 PM Jenburkt Pharma - Quaterly Results 6 Feb, 4:29 PM Jenburkt Pharma - Quaterly Results 6 Feb, 4:29 PM Jenburkt Pharmaceuticals informs about loss of share certificate 13 Dec, 5:16 PM Jenburkt Pharma - Quaterly Results 7 Nov, 4:41 PM Jenburkt Pharma - Quaterly Results 7 Nov, 4:41 PM Jenburkt Pharmaceuticals informs about loss of share certificate 9 Aug, 2:18 PM Jenburkt Pharma - Quaterly Results 8 Aug, 5:04 PM Jenburkt Pharma - Quaterly Results 8 Aug, 5:04 PM Jenburkt Pharma - Quaterly Results 8 Aug, 5:04 PM Jenburkt Pharmaceuticals informs about loss of share certificate 14 Jul, 4:44 PM Jenburkt Pharmaceuticals informs about loss of share certificates 7 Jul, 2:18 PM Jenburkt Pharma - Quaterly Results 23 May, 5:19 PM Jenburkt Pharma - Quaterly Results 23 May, 5:19 PM Jenburkt Pharma - Quaterly Results 23 May, 5:19 PM Jenburkt Pharmaceuticals informs about board meeting 12 May, 4:59 PM Jenburkt Pharmaceuticals informs about disclosure 14 Mar, 12:55 PM Jenburkt Pharmaceuticals informs about disclosure 2 Mar, 5:08 PM Jenburkt Pharmaceuticals informs about newspaper publication 8 Feb, 1:15 PM Jenburkt Pharma - Quaterly Results 7 Feb, 5:26 PM Jenburkt Pharma - Quaterly Results 7 Feb, 5:26 PM Jenburkt Pharma - Quaterly Results 7 Feb, 5:26 PM Jenburkt Pharmaceuticals submits daily report 12 Jan, 5:33 PM Jenburkt Pharmaceuticals informs about disclosure 22 Dec, 10:37 AM Jenburkt Pharmaceuticals informs about outcome of board meeting 1 Dec, 4:16 PM Jenburkt Pharma - Quaterly Results 8 Nov, 3:47 PM

Jenburkt Pharma Stock Price Analysis and Quick Research Report. Is Jenburkt Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Jenburkt Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Jenburkt Pharma has a PE ratio of 14.5164537949575 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Jenburkt Pharma has ROA of 17.8602% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Jenburkt Pharma has a Current ratio of 3.0039.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Jenburkt Pharma has a ROE of 20.2456%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Jenburkt Pharma has a Debt to Equity ratio of 0.0115 which means that the company has low proportion of debt in its capital.

  • Sales growth: Jenburkt Pharma has reported revenue growth of 6.8502% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Jenburkt Pharma for the current financial year is 26.628057603755%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Jenburkt Pharma is Rs 18 and the yield is 1.7919%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Jenburkt Pharma is Rs 73.5028. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Jenburkt Pharma in Ticker for free. Also, one can get the intrinsic value of Jenburkt Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Jenburkt Pharma FAQs

Q1. What is Jenburkt Pharma share price today?
Ans: The current share price of Jenburkt Pharma is Rs 1067.

Q2. What is the market capitalisation of Jenburkt Pharma?
Ans: Jenburkt Pharma has a market capitalisation of Rs 470.89911 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Jenburkt Pharma?
Ans: The PE ratio of Jenburkt Pharma is 14.5164537949575 and the P/B ratio of Jenburkt Pharma is 2.62236902901073, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Jenburkt Pharma share?
Ans: The 52-week high share price of Jenburkt Pharma is Rs 1410, and the 52-week low share price of Jenburkt Pharma is Rs 920.2.

Q5. Does Jenburkt Pharma pay dividends?
Ans: Currently, Jenburkt Pharma pays dividends. Dividend yield of Jenburkt Pharma is around 1.7919%.

Q6. What are the face value and book value of Jenburkt Pharma shares?
Ans: The face value of Jenburkt Pharma shares is Rs 10, while the book value per share of Jenburkt Pharma is around Rs 406.884. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Jenburkt Pharma?
Ans: Jenburkt Pharma has a total debt of Rs 1.9788 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Jenburkt Pharma?
Ans: The ROE of Jenburkt Pharma is 20.2456% and ROCE of Jenburkt Pharma is 27.8545%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Jenburkt Pharma a good buy for the long term?
Ans: The Jenburkt Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Jenburkt Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Jenburkt Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Jenburkt Pharma’s financials?
Ans: You can review Jenburkt Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Jenburkt Pharma
X